52: Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation (HCT) A report from the bone marrow transplant survivor study (BMT-SS) by Baker, K.S. et al.
mune responses. We present results of an ongoing Phase I clinical
trial of haplo-mismatched allogeneic stem cell transplant (SCT) sup-
plemented with donor lymphocyte infusions (DLIs) PDT depleted of
host-reactive T cells. Nine high-risk patients with hematologic ma-
lignancies (5 AML relapsed or refractory, 2 MDS, 1 NHL, 1 refrac-
tory CLL) entered the trial, 7 (4 M, 3 F) are evaluable for acute
GVHD and immune reconstitution. Donor mononuclear cells
(MNCs) were incubated with recipient MNCs for 4 days, exposed to
TH9402 PDT, stored frozen, and administered on day 30	3 after
transplant at 3 graded DLI dose levels: 1104 (1pt), 5104 (3pts), and
1.3 105 (3pts) CD3 cells/kg. Anti-host cytotoxic T lymphocyte
precursors (CTLp) were depleted from DLIs by approximately 1.5
logs, and ﬂow cytometry showed greater than 90% elimination of
activated T cells (CD4CD25 and CD8CD25) by TH9402
PDT. Median age at SCT was 57 years (range: 40-58). The myeloa-
blative regimen consisted of TBI (1200 cGy), thiotepa (5 mg/kg) and
ﬂudarabine (40 mg/m2/day for 5 days) followed by infusion of CD3
depleted HSC grafts. No GVHD prophylaxis was administered.
Evaluable patients showed durable trilineage hematologic engraft-
ment and achieved complete donor chimerism. No patient developed
acute GVHD (grade II-IV), while 3 patients developed signs of
chronic GVHD. Two patients died: one (cohort 1) of a post-trans-
plant lymphoproliferative disease, and one (cohort 2), of relapsed
AML. No other patient relapsed. Two pts recovered greater than
0.3109 CD3 and CD4 cells/L at 2 and 5 months post-DLI, and
4 pts had 0.2109 CD3 cells/L at 6 mo post-DLI. Although 4
patients developed infectious complications (HSV, CMV, Nocardia,
Aspergillus), all resolved rapidly with appropriate therapy. The overall
disease-free-survival and survival are 57% at 1 year (median follow-up:
9.4 mo). Our results indicate that the post-transplant infusion of a
PDT treated DLI is feasible, does not induce acute GVHD, and may
accelerate T cell reconstitution.
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ENHANCED DEPLETION OF ALLOREACTIVE T CELLS USING COMBINED
CD25/71 IMMUNOMAGNETIC SELECTION
Samarasinghe, S.1, Karlsson, H.1, Nawroly, N.2, Openshaw, P.2, Veys, P.3,
Amrolia, P.1,3 1Institute of Child Health, London, United Kingdom; 2St.
Mary’s Hospital, Imperial College, London, United Kingdom; 3Great
Ormond Street Hospital for Children, London, United Kingdom.
Immunotherapy with allodepleted donor T-cells generated using
a CD25 immunotoxin improves immune reconstitution after
haplo-SCT, but leukaemic relapse remains a problem. To develop
a rational approach to reﬁning allodepletion, we characterised the
phenotype of proliferating alloreactive T cells ﬂow cytometrically.
CFSE-labelled T cells were co-cultured with HLA-mismatched
dendritic cells and serial FACS analyses performed to determine
expression of CD25, CD69, CD71, HLA-DR, OX40, ICOS,
CD95, CD45RA, CCR7, IFN, TNF, and IL-2. By staining each
sample with CD3, CFSE and CD25 we were able to determine the
phenotype of proliferating CD25 negative alloreactive T cells. In 5
donors, after a 3 day culture, CD25 was expressed in a mean of 83
% (67-89 %) of the proliferating (CFSE-dim) alloreactive T cells,
conﬁrming CD25 as an excellent target for allodepletion. 70 %
(39-81 %) of the proliferating alloreactive CD25 -ve population
expressed CD71, and 62 % (50-74 %) expressed CD45RA, iden-
tifying these two molecules, as markers of alloreactive T cells that
would be retained after CD25 based allodepletion. We then com-
pared residual alloreactivity after CD25 vs CD25/71 vs CD25/
45RA based allodepletion using negative selection with immuno-
magnetic beads in 5 HLA-mismatched donors-recipient pairs.
Primary MLRs showed a mean residual proliferation to host of
0.58 % (0-2.7 %) after CD25 depletion, 1.73 % (0– 7.6 %) after
CD25/45RA depletion and 0.04 % (0-0.2 %) for CD25/71 deple-
tion. IFN- ELISPOT analyses demonstrated that when recul-
tured with original stimulator, CD25 depletion led to a mean 88 %
reduction in IFN SFC compared to unmanipulated sensitized
PBMCs and this was enhanced by CD25/71 (95 %) or CD25/
45RA depletion (93 %) with third party responses maintained for
all 3 arms. In secondary MLRs, the mean residual proliferations to
the original stimulator was: CD25 allodepletion 0.71 % (0-1.14
%), CD25/CD71 0.01 %, (0-0.04 %) (CD25 vs CD25/71 p0.06)
and for CD25/CD45RA 14.85 % ( 0-33.09 %)(CD25 vs CD25/
45RA p0.028). Studies demonstrating preservation of antiviral
responses after CD25/71 depletion will be presented. We conclude
that CD25/71 allodepletion will selectively delete  90% of the
proliferating alloreactive T cells and enhances the depletion of
alloreactivity compared with CD25-based methods. This strategy
may facilitate immunotherapy with larger doses of allodepleted
donor T-cells after haplo-SCT, enhancing graft versus leukaemia
and antiviral effects.
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ANDROGEN WITHDRAWAL MODULATES THYMOPOIESIS BY INDUCING
THYMIC EPITHELIAL CELL PROLIFERATION AND ENHANCING THYMO-
CYTE DEVELOPMENT PRIOR TO INCREASING PRECURSOR IMMIGRA-
TION
Williams, K.M.1, Chu, Y.-W.1, Tayler, E.1, Gress, R.E.1 1Experimen-
tal Transplantation and Immunology Branch/NCI/NIH, Bethesda, MD.
Impaired thymopoiesis contributes to immune deﬁciency in ag-
ing, AIDS, and following allogeneic bone marrow transplantation.
Little is known of the mechanisms of thymic regulation. We show
that castration of male mice resulted in increased thymic size,
thymocyte number, intrathymic T cell receptor excision circles,
and the number of early thymic progenitors (ETP: Lin- CKIT hi
CD44 hi) as early as eight days post-castration. These observations
suggested a mechanism of enhanced thymopoieis that occurs
through increased immigration of thymocyte precursors presum-
ably due to increased circulating progenitors. However, the earliest
T cell progenitor population in the bone marrow (LSK: Lin-, c-kit
hi, Sca-1, IL7Ra-) was not increased in castrated mice. In addi-
tion, statistically signiﬁcant increases in thymocyte number and
early thymus subsets occurred on day 5, prior to the increase in
thymic ETPs (day 8). Five days post-castration, there was a statis-
tically signiﬁcant doubling of double negative (DN) thymocytes,
with the greatest increases in the DN3 and DN4 populations.
Double positive (DP) thymocytes (CD4CD8) were signiﬁ-
cantly increased as well. Furthermore, there was evidence of sig-
niﬁcantly increased proliferation of DN3 and increased transit into
DP thymocytes determined by bromodeoxyuridine (BRDU) incor-
poration reﬂected in DN3 and DP thymocytes at this time point.
These data suggest that intrathymic maturation of primitive thy-
mocytes is important early in the mechanism of enhanced thymo-
poiesis following androgen withdrawal. Preliminary data also dem-
onstrate a concomitant increase in the percentage of BRDU 
thymic epithelial cells (TEC) at day5, implicating stromal prolif-
eration in thymic expansion. Immunohistochemistry analyses using
laser scanning cytometery suggest an increase in both cortical and
medullary TEC subsets following castration. Finally, preliminary
adoptive transfer studies with congenic LSK suggest enhanced
uptake of ETP occur after these intrathymic changes. These data
suggest that androgen withdrawal leads to proliferation of thymic
epithelial cell subsets with enhanced maturation of early thymo-
cytes, followed by increased ETP entry into the thymus. These
studies have implications for enhanced thymopoiesis following
marrow transplant and identify two points of thymic regulation: 1)
TEC proliferation and 2) ETP entry into the thymus.
LATE EFFECTS/QUALITY OF LIFE
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LATE EFFECTS IN SURVIVORS OF ACUTE LEUKEMIA TREATED WITH
HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A REPORT FROM
THE BONE MARROW TRANSPLANT SURVIVOR STUDY (BMT-SS)
Baker, K.S.1, Ness, K.1, Weisdorf, D.1, Francisco, L.2, Carter, A.2,
Sun, C.-L.2, Forman, S.2, Bhatia, S.2 1Departments of Pediatrics and
Medicine, University of Minnesota, Minneapolis, MN; 2City of Hope
National Medical Center, Duarte, CA.
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HCT is a common treatment for patients with high risk or
relapsed AML or ALL, although speciﬁc late effects in AML or
ALL survivors after HCT have not been well described. The
BMT-SS is a retrospective cohort study in which participants
completed a 255 item questionnaire on late effects occurring
after HCT. Eligible subjects received HCT between 1974-1998,
were 18 years or older at the time of interview and had survived
for 2 yrs after HCT. A random sample of 319 siblings of study
participants was recruited for comparison. The study included
253 survivors with AML and 100 with ALL. Mean age at HCT
was 32yr AML/22yr ALL (1.7-63yr), and the mean age at
interview was 41yr AML/34yr ALL (18-67yr), and 44yr (19-
79yr) for siblings. Subjects survived a mean of 10yr (2-25yr)
after HCT. Donor source was related (57% AML, 75% ALL),
autologous (35% AML, 18% ALL) or unrelated (8% AML, 7%
ALL); 82% from marrow, 17% from peripheral blood /-
marrow, and 0.8% cord blood. 82% of AML and 100% of ALL
subjects received TBI. The frequencies of late effects did not
differ between ALL and AML survivors. Compared to siblings,
survivors had a signiﬁcantly higher frequency of diabetes (DM,
9% vs 3%, p0.001), hypothyroidism (22% vs 7%, p0.001),
osteoporosis (9% vs 2%, p0.001), exercise induced shortness
of breath (EISB, 7% vs 2%, p0.006, neurosensory impair-
ments (30% vs 20%, p0.001), and problems with balance,
tremor or weakness (14% vs 5%, p0.001). Survivors also
reported signiﬁcantly higher frequency of requiring assistance
with activities of daily living, and having their health status
prevent school or work attendance. In multivariable analysis, the
risk of these outcomes did not differ by diagnosis. Survivors
after allogeneic HCT had higher odds of DM (odds ratio [OR]
3.92, 95% conﬁdence interval [CI] 1.09-14.01), osteoporosis
(OR 3.1, 95% CI 1.02-9.43), cardiopulmonary impairments
(OR 1.93, 95% CI 1.1-3.38), and abnormal sense of touch (OR
2.55, 95% CI 1.19-5.45) and were also more likely to have
difﬁculties with routine activities (OR 4.63, 95% CI 1.30-
16.54), and to report their overall health as fair or poor (OR
2.15, 95% CI 1.09-4.24). Those with a history of chronic
GVHD had signiﬁcantly higher odds of having EISB, neuro-
sensory impairments, and inability to attend school or work due
to their health. Ongoing surveillance for these late effects and
appropriate interventions are required to improve the health
status of ALL and AML survivors after HCT.
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ACCESS TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EFFECT
OF RACE AND GENDER
Joshua, T.V.1, Rizzo, J.D.1, Zhang, M.-J.1, Horowitz, M.M.1 1Center
for International Blood and Marrow Transplant Research, Medical Col-
lege of Wisconsin, Milwaukee, WI.
Background
Although Hematopoietic Stem Cell Transplantation (HCT)
has the potential to increase survival for patients with many
diseases, particularly hematologic cancers, it is a complex and
costly procedure with substantial risk of morbidity and mortal-
ity. Increasing numbers of uninsured and underinsured persons
and health care marketplace competition raise concerns about
patients’ access to HCT in the United States. Many studies
demonstrate that African-Americans are more likely to be diag-
nosed at advanced stages of cancer and are less likely to receive
optimal care for cancer than Caucasians and that women are less
likely to receive some aggressive interventions than men. In this
study, we addressed the question of whether African-Americans
and women are would be less likely to receive HCT for hema-
tologic malignancy.
Methods
We estimated the annual incidence of leukemia, lymphoma
and multiple myeloma for African-Americans, Caucasians, men
and women under the age of 70 years in the U.S. using the
SEER Cancer Registry and U.S. Census reports. We estimated
the annual incidence of autologous, HLA-identical sibling and
unrelated HCT performed in these groups in the U.S. using
CIBMTR registration data for 1997 to 2002. Logistic regression
was used to calculate the age-adjusted odds ratio of receiving
HCT in groups deﬁned by race, gender and disease.
Results
The overall likelihood (or odds) of undergoing HCT for the
diseases considered was higher for Caucasians than for African-
Americans [OR1.40(1.34-1.46)]. This difference in likelihood
persisted for each type of HCT: autologous [OR1.24(1.19-
1.30)], HLA identical sibling [OR1.59(1.46-1.74)], and unre-
lated donor [OR2.02(1.75-2.33)]. Men were somewhat more
likely to receive HCT than women [OR1.07(1.05-1.1)]; how-
ever, this difference pertained only to autologous transplanta-
tion [OR1.1(1.06-1.13)]. The likelihoods of HLA identical
sibling [OR1.05(0.99-1.10)] and unrelated donor HCT
[OR0.94(0.88-1.01)] did not differ signiﬁcantly by gender.
Conclusions
Utilization of HCT for leukemia, lymphoma and multiple my-
eloma varies by race, with Caucasians more likely to receive HCT
than African-Americans. Lower HCT rates for African-Americans
were seen for both autologous and allogeneic HCT, indicating that
donor availability cannot fully explain the differences. Women
with lymphoma and multiple myeloma are also less likely than men
to receive autologous HCT for reasons unexplained by age or
disease status.
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HEMATOPOIETIC CELL TRANSPLANTATION-COMORBIDITY INDEX
(HCT-CI): A VALID TOOL TO PREDICT MORBIDITY RISK IN PATIENTS
UNDERGOING AUTOLOGOUS HCT (AHCT) FOR LYMPHOMA
Kassar, M.1, Shell, K.1, Gregory, S.A.1, Venugopal, P.1, Shammo, J.1,
Fung, H.C.1 1Rush University Medical Center, Chicago, IL.
Background: HCT-CI provided valid scoring of pretrans-
plant comorbidities that predicted non-relapse mortality and
survival for patients (pts) undergoing allogeniec HCT. It is
more sensitive and greater survival predictor than Charlson
Comorbidity Index (CCI). (Ref: M. Sorror et al, Blood Oct/05,
Vol 106). Objectives: To evaluate the predictive value of
HCT-CI and CCI for morbidity risk assessment in pts with
lymphoma undergoing AHCT. Morbidity was measured by the
duration of hospitalization (DOH) and the incidence of Hospi-
tal Re-Admission within 100 days post-AHCT (HRA-100).
Methods: We included pts with history of Hodgkin or non-
Hodgkin lymphoma (HL or NHL) who underwent AHCT in
our institution between 01/98 and 05/06. Since the prevalence
of comorbidities is less before the age of 40, only pts above this
age were included. Pts were given scores based on the HCT-CI
and CCI (table). Prior solid tumor comorbidity was excluded.
Results: 80 pts met the inclusion criteria , 74 had NHL and 6
had HL. 61 pts were male. Median age was 56 years (42-76).
Median DOH was 21 days (12-36). Median HCT-CI was 1: 37
% of pts had score 0, 26% had score 1, and 37 % had scores 2
to 7. Median CCI was 1: 46% of pts had score 0, 31% had score
1, and 23% had scores 2 to 3. 16 pts (20%) required HRA-100.
After adjustment for age at transplantation and type of condi-
tioning regimens, HCT-CI was signiﬁcantly correlated with the
DOH (p0.027, HR: 0.86), whereas the CCI was not (p 0.06,
HR: 0.79). Both HCT-CI and CCI were signiﬁcant predictors
for HRA-100 (p0.009, OR: 1.51; p 0.017, OR: 2.08, respec-
tively). Conclusion: HCT-CI predicted the morbidity risk after
AHCT for pts with lymphoma. Both HCT-CI and CCI were
strong predictors for the risk of HRA-100. HCT-CI is more
valid and reliable than CCI in predicting the DOH. HCT-CI
can serve as important tool for both the transplant administrator
when planning for resources allocation, and for patients during
pre-transplant evaluation and counseling.
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